Prenetics Global Limited (PRE)

Market Cap	70.98M
Revenue (ttm)	10.61M
Net Income (ttm)	-62.99M
Shares Out	12.22M
EPS (ttm)	-5.42
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	5,885
Open	5.56
Previous Close	5.50
Day's Range	5.56 - 6.00
52-Week Range	2.85 - 13.59
Beta	-0.16
Analysts	Buy
Price Target	9.00 (+50.0%)
Earnings Date	Jun 18, 2024

About PRE

Prenetics Global Limited, a genomics-driven health sciences company, engages in prevention, early detection, and treatment. It operates through two segments: Prevention and Diagnostics. Its prevention arm, CircleDNA, uses whole exome sequencing to offer comprehensive consumer DNA test. It also develops and commercializes Insighta, a multi-cancer early detection technology. In addition, the company offers a range of genomic profiling panels tailored for requirements and clinician needs, including ACTOnco, ACT HRD, ACTFusion, and ACTDrug tests. F...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 2014
• Employees: 320
• Stock Exchange: NASDAQ
• Ticker Symbol: PRE

Financial Performance

In 2023, PRE's revenue was $21.74 million, an increase of 65.17% compared to the previous year's $13.16 million. Losses were -$62.72 million, -67.07% less than in 2022.

Analyst Forecast

According to one analyst, the rating for PRE stock is "Buy" and the 12-month stock price forecast is $9.0.

Price Target

$9.0

(50.00% upside)

Analyst Consensus: Buy